Compare KNRX & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNRX | KRRO |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 58.6M |
| IPO Year | 2025 | 2019 |
| Metric | KNRX | KRRO |
|---|---|---|
| Price | $1.98 | $7.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $74.17 |
| AVG Volume (30 Days) | 29.5K | ★ 1.1M |
| Earning Date | 06-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,820,365.00 | $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.00 | N/A |
| 52 Week Low | $1.25 | $5.20 |
| 52 Week High | $4.00 | $55.89 |
| Indicator | KNRX | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 27.15 |
| Support Level | N/A | $5.20 |
| Resistance Level | N/A | $6.59 |
| Average True Range (ATR) | 0.00 | 0.51 |
| MACD | 0.00 | 0.75 |
| Stochastic Oscillator | 0.00 | 89.19 |
Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. Its software offers marketers cost-effective solutions and productivity-enhancing capabilities to target audience across various advertising channels and devices through automated processes and algorithms, which is known as programmatic advertising. Its product, Knorex XPOSM, is a self-service enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications. The Company operates in one operating segment, which focuses on platform subscription fee, platform services, managed activations, and professional services.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.